Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatment approved ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

You have permission to edit this article. Edit Close Newsletter Facebook ...

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...

Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically for this condition. This would translate to Pfizer saving ...